Patrick Hagen

9PUBLICATIONS
16CO-AUTHORS
Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 17, 2026
Temporal trends and demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER database (1999-2022).

|Sep 09, 2025
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).

Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala

|Aug 27, 2025
Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma.

Benjamin Massat, Patrick Stiff, Fatema Esmail

|Aug 14, 2025
Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15).

Yvonne Efebera, Vera Suman, Shira Dinner

|Jan 04, 2024
Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.

Patrick Hagen, Joseph Norton, Stephanie Tsai

|May 31, 2022
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.

Patrick Hagen, Jiwang Zhang, Kevin Barton

Pageof 2

Frequent Collaborators

1 joint publications

Sidharth Mahajan

1 joint publications

Stephanie Berg

1 joint publications

Ami Dave

1 joint publications

Elizabeth Elliott